Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Other financing activities (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Other financing activities for 11 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • Quarterly Other financing activities fell 53.27% to $1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.4 million through Dec 2025, down 71.01% year-over-year, with the annual reading at $283000.0 for FY2025, 88.57% down from the prior year.
  • Other financing activities hit $1.1 million in Q4 2025 for Coherus Oncology, up from $3000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $4.6 million in Q4 2022 to a low of -$2.0 million in Q2 2021.
  • Historically, Other financing activities has averaged $843750.0 across 5 years, with a median of $313000.0 in 2022.
  • Biggest five-year swings in Other financing activities: tumbled 109.11% in 2021 and later skyrocketed 2658.33% in 2022.
  • Year by year, Other financing activities stood at -$180000.0 in 2021, then surged by 2658.33% to $4.6 million in 2022, then plummeted by 104.32% to -$199000.0 in 2023, then skyrocketed by 1322.61% to $2.4 million in 2024, then plummeted by 53.27% to $1.1 million in 2025.
  • Business Quant data shows Other financing activities for CHRS at $1.1 million in Q4 2025, $3000.0 in Q3 2025, and $16000.0 in Q2 2025.